These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 19129523)

  • 1. The Neurontin legacy--marketing through misinformation and manipulation.
    Landefeld CS; Steinman MA
    N Engl J Med; 2009 Jan; 360(2):103-6. PubMed ID: 19129523
    [No Abstract]   [Full Text] [Related]  

  • 2. Shifting terrain in the regulation of off-label promotion of pharmaceuticals.
    Mello MM; Studdert DM; Brennan TA
    N Engl J Med; 2009 Apr; 360(15):1557-66. PubMed ID: 19357413
    [No Abstract]   [Full Text] [Related]  

  • 3. Pfizer pleads guilty, but drug sales continue to soar.
    Lenzer J
    BMJ; 2004 May; 328(7450):1217. PubMed ID: 15155480
    [No Abstract]   [Full Text] [Related]  

  • 4. Doctor explains why he blew the whistle.
    Petersen M
    N Y Times Web; 2003 Mar; ():C1, C2. PubMed ID: 12812161
    [No Abstract]   [Full Text] [Related]  

  • 5. Teaching clinicians about drugs--50 years later, whose job is it?
    Avorn J
    N Engl J Med; 2011 Mar; 364(13):1185-7. PubMed ID: 21449781
    [No Abstract]   [Full Text] [Related]  

  • 6. Forbidden and Permitted Statements about Medications--Loosening the Rules.
    Avorn J; Sarpatwari A; Kesselheim AS
    N Engl J Med; 2015 Sep; 373(10):967-73. PubMed ID: 26332553
    [No Abstract]   [Full Text] [Related]  

  • 7. A historical perspective of pharmaceutical promotion and physician education.
    Podolsky SH; Greene JA
    JAMA; 2008 Aug; 300(7):831-3. PubMed ID: 18714063
    [No Abstract]   [Full Text] [Related]  

  • 8. Drug maker to pay $430 million in fines, civil damages.
    FDA Consum; 2004; 38(4):36-7. PubMed ID: 15346583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Court papers suggest scale of drug's use: lawsuit says doctors were paid endorsers.
    Petersen M
    N Y Times Web; 2003 May; ():C1, C2. PubMed ID: 12812176
    [No Abstract]   [Full Text] [Related]  

  • 10. Off-label or off-limits?
    Ratner M; Gura T
    Nat Biotechnol; 2008 Aug; 26(8):867-75. PubMed ID: 18688236
    [No Abstract]   [Full Text] [Related]  

  • 11. Unique Origins of Modern Opioid Marketing and the Link to the Opioid Epidemic: A Historical Perspective.
    Hooten KM; Hooten WM
    Pain Med; 2019 Aug; 20(8):1638-1639. PubMed ID: 30916752
    [No Abstract]   [Full Text] [Related]  

  • 12. False Claims Act prosecution did not deter off-label drug use in the case of neurontin.
    Kesselheim AS; Darby D; Studdert DM; Glynn R; Levin R; Avorn J
    Health Aff (Millwood); 2011 Dec; 30(12):2318-27. PubMed ID: 22147859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dicing with death : there's a good chance that the pills your doctor prescribed will do you no good and might even harm you.
    Muir H
    New Sci; 2006 Jul 29-Aug 4; 191(2562):38-41. PubMed ID: 17115486
    [No Abstract]   [Full Text] [Related]  

  • 14. Vioxx's history and the need for better procedures and better testing.
    Gilhooley M
    Seton Hall Law Rev; 2007; 37(4):941-68. PubMed ID: 18363218
    [No Abstract]   [Full Text] [Related]  

  • 15. Pfizer versus Kaiser: insurers want their day in court.
    Silverman E
    BMJ; 2013 Jun; 346():f3738. PubMed ID: 23760967
    [No Abstract]   [Full Text] [Related]  

  • 16. Direct-to-consumer prescription drug advertising: history, regulation, and issues.
    Huh J; DeLorme DE; Reid LN; An S
    Minn Med; 2010 Mar; 93(3):50-2. PubMed ID: 20429178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Vernacular of Risk--Rethinking Direct-to-Consumer Advertising of Pharmaceuticals.
    Greene JA; Watkins ES
    N Engl J Med; 2015 Sep; 373(12):1087-9. PubMed ID: 26287749
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmaceutical promotion to physicians and First Amendment rights.
    Kesselheim AS; Avorn J
    N Engl J Med; 2008 Apr; 358(16):1727-32. PubMed ID: 18420505
    [No Abstract]   [Full Text] [Related]  

  • 19. Presumption of innocence: FDA's authority to regulate the specifics of prescription drug labeling and the preemption debate.
    Dorfman HL; Quinn VM; Brophy EA
    Food Drug Law J; 2006; 61(4):585-622. PubMed ID: 17180765
    [No Abstract]   [Full Text] [Related]  

  • 20. Historical perspectives on the marketing of medicines.
    Smith MC
    Publ Am Inst Hist Pharm; 1997; 16():263-76. PubMed ID: 11619898
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.